SYROS PHARMACEUTICALS INC's ticker is SYRS and the CUSIP is 87184Q107. A total of 95 filers reported holding SYROS PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.46 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2022 | $22,000 | -87.9% | 22,393 | -85.4% | 0.00% | – |
Q1 2022 | $182,000 | -43.5% | 153,702 | +55.8% | 0.00% | – |
Q4 2021 | $322,000 | -57.3% | 98,645 | -41.5% | 0.00% | – |
Q3 2021 | $754,000 | -44.4% | 168,628 | -32.2% | 0.00% | – |
Q2 2021 | $1,356,000 | -78.7% | 248,648 | -70.7% | 0.00% | -100.0% |
Q1 2021 | $6,356,000 | +177.4% | 849,782 | +302.4% | 0.00% | – |
Q4 2020 | $2,291,000 | +1609.7% | 211,177 | +1579.3% | 0.00% | – |
Q2 2020 | $134,000 | +1.5% | 12,575 | -47.1% | 0.00% | – |
Q4 2018 | $132,000 | -29.0% | 23,759 | +30.5% | 0.00% | – |
Q2 2018 | $186,000 | -80.9% | 18,207 | -72.5% | 0.00% | -100.0% |
Q3 2017 | $975,000 | – | 66,249 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Ally Bridge Group (NY) LLC | 3,139,895 | $23,486,000 | 4.50% |
Samsara BioCapital, LLC | 2,189,199 | $14,769,000 | 2.72% |
Bain Capital Life Sciences Investors, LLC | 5,785,036 | $43,272,000 | 2.45% |
Omega Fund Management, LLC | 1,562,500 | $11,688,000 | 1.11% |
Flagship Pioneering Inc. | 2,938,494 | $21,980,000 | 0.35% |
EcoR1 Capital, LLC | 1,000,000 | $7,480,000 | 0.33% |
Altium Capital Management LP | 126,702 | $948,000 | 0.26% |
Nikko Asset Management Americas, Inc. | 5,042,009 | $37,714,000 | 0.18% |
Artal Group S.A. | 1,025,000 | $7,667,000 | 0.14% |
Orbimed Advisors | 1,837,500 | $13,745,000 | 0.13% |